H pylori eradication:A randomized prospective study of triple therapy with or without ecabet sodium
H pylori eradication:A randomized prospective study of triple therapy with or without ecabet sodium作者机构:Department of Internal Medicine Bongseng Memorial Hospital Busan Korea Department of Internal Medicine Pusan National University School of Medicine Busan 602-739 Korea Department of Internal Medicine Maryknoll Hospital Busan Korea
出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))
年 卷 期:2008年第14卷第6期
页 面:908-912页
核心收录:
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金:An unrestricted grant by JEIL Pharm.Co. Ltd. Korea
主 题:H pylori Eradication Triple therapy Ecabet sodium
摘 要:AIM: To investigate whether adding ecabet sodium to the standard triple therapy for H pylori infection improve eradication rate. METHODS: Two hundred and fifty-seven H pylori-infected patients were randomly assigned to standard triple therapy (group A, n = 129) or triple therapy plus ecabet sodium (group B, n = 128). Successful eradication was defined as a negative 13C-urea breath test 6-8 wk after completion of treatment. RESULTS: After completion of therapy, 194/257 patients showed negative 13C-urea breath test results. According to intention-to-treat analysis, the infection was eradicated in 93/129 (72.1%) patients in group A and 101/128 (78.9%) in group B (P = 0.204). Per-protocol analysis showed successful eradication in 93/118 (78.8%) patients from group A and 101/114 (88.6%) from group B (P = 0.044). There were no significant differences in the side effects experienced by the patients in the two treatment groups. CONCLUSION: Our results suggest that the addition of ecabet sodium improves the efficacy of the standard triple therapy for H pylori.